As the opioid epidemic continues to grip the US as the leading cause of deaths in those under the age of 50, the FDA has made an important leap with the approval of Lucemyra (lofexidine hydrochloride) for managing the symptoms of opioid withdrawal in adult patients - the first non-opioid therapy for this purpose.

More From BioPortfolio on "FDA green lights first non-opioid therapy to manage symptoms of opioid withdrawal"

Relevant Topic

Drug ApprovalsIn order to become availible to pateints, drugs need to undergo a number of phases of clinical trials to test their efficacy and safty and to then be authorised by the drug approval organistion in each respective country. This is the FDA in the USA and N...